• LAST PRICE
    0.0503
  • TODAY'S CHANGE (%)
    Trending Down-0.0096 (-16.0267%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0599 / 0.0599
  • Day Range
    Low 0.0250
    High 0.0599
  • 52 Week Range
    Low 0.0250
    High 0.2590
  • Volume
    634,047
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.0599
TimeVolumeOTLC
09:32 ET22500.0599
09:46 ET840000.04
09:48 ET2255150.0545
09:50 ET10000.045
09:55 ET225000.05
09:57 ET275000.0498
10:06 ET588380.045
10:08 ET50000.05
10:18 ET50000.048
10:40 ET150000.049
10:47 ET25000.049
10:56 ET25000.048
11:18 ET544800.0481
11:50 ET328880.05
12:17 ET35560.05
12:39 ET331500.051
12:44 ET430000.055
12:55 ET100000.055
01:38 ET50000.0501
02:34 ET3700.0503
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOTLC
Oncotelic Therapeutics Inc
19.7M
2.7x
---
United StatesNRSN
Neurosense Therapeutics Ltd
19.7M
0.0x
---
United StatesBLPH
Bellerophon Therapeutics Inc
20.0M
-1.0x
---
United StatesZVSA
Zyversa Therapeutics Inc
19.1M
-10.3x
---
United StatesRGRX
RegeneRx Biopharmaceuticals Inc
20.1M
-11.2x
---
United StatesKTTA
Pasithea Therapeutics Corp
20.4M
-2.1x
---
As of 2023-01-29

Company Information

Oncotelic Therapeutics, Inc. is an immuno-oncology company. The Company is engaged in the development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. ArtiVeda/ArtiShield is a natural derivative from the plant Artemisia. Artemisinin derivatives are used to treat malaria. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with focus on childhood leukemia.

Contact Information

Headquarters
29397 Agoura Road Suite 107AGOURA HILLS, CA, United States 91301
Phone
650-635-7000
Fax
650-635-7001

Executives

Chairman of the Board, Chief Executive Officer
Vuong Trieu
Chief Financial Officer
Amit Shah
Chief Regulatory Officer
Seymour Fein
Chief Business Officer
Saran Saund
Chief Medical Officer
Fatih Uckun

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$19.7M
Revenue (TTM)
$0.00
Shares Outstanding
391.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.66
EPS
$0.02
Book Value
$0.02
P/E Ratio
2.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
2.4x
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.